| (Values in U.S. Thousands) | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 |
| Sales | 260 | 1,110 | 1,140 | 1,950 | 3,520 |
| Sales Growth | -76.58% | -2.63% | -41.54% | -44.60% | +29.89% |
| Net Income | -2,400 | -2,650 | -3,610 | -9,710 | -2,660 |
| Net Income Growth | +9.43% | +26.59% | +62.82% | -265.04% | +78.96% |
Cleveland Biolabs (CBLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cytocom Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Cytocom Inc., formerly known as Cleveland BioLabs Inc., is based in FORT COLLINS, Colo.